Immunomedics (NASDAQ: IMMU) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Institutional & Insider Ownership

64.5% of Immunomedics shares are held by institutional investors. Comparatively, 48.0% of Protagonist Therapeutics shares are held by institutional investors. 6.6% of Immunomedics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Immunomedics and Protagonist Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunomedics -4,956.52% N/A -109.37%
Protagonist Therapeutics N/A -59.45% -54.53%

Analyst Recommendations

This is a breakdown of current recommendations for Immunomedics and Protagonist Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunomedics 0 0 3 0 3.00
Protagonist Therapeutics 0 0 2 0 3.00

Immunomedics currently has a consensus price target of $14.50, suggesting a potential upside of 3.72%. Protagonist Therapeutics has a consensus price target of $40.50, suggesting a potential upside of 129.20%. Given Protagonist Therapeutics’ higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Immunomedics.

Valuation and Earnings

This table compares Immunomedics and Protagonist Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Immunomedics $3.09 million 503.46 -$71.33 million ($1.43) -9.78
Protagonist Therapeutics N/A N/A -$47.60 million ($3.27) -5.40

Protagonist Therapeutics has higher revenue, but lower earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.


Immunomedics beats Protagonist Therapeutics on 6 of the 10 factors compared between the two stocks.

Immunomedics Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.